{"DataElement":{"publicId":"2688790","version":"2","preferredName":"Chronic Myelogenous Leukemia Classification Type","preferredDefinition":"A description of chronic myelogenous leukemia classification.","longName":"CML_CLS_TP","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2688788","version":"1","preferredName":"Chronic Myelogenous Leukemia Classification","preferredDefinition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival._A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","longName":"CML_CLS","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2500393","version":"1","preferredName":"CML","preferredDefinition":"The most common chronic myeloproliferative disorder characterized by neutrophilic leukocytosis.  It is associated with the Philadelphia (Ph) chromosome and/or the BCR/ABL fusion gene.  Most patients are middle-aged or elderly.  Common findings at presentation include fatigue, weight loss, anemia, night sweats, and splenomegaly.  The disease is bi- or triphasic: an initial indolent chronic phase is followed by accelerated or blast phase.  Allogeneic bone marrow transplantation is currently the only curative therapy (adapted from WHO 2001).  -- 2003","longName":"C3174","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3174","definition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1995DB3E-65B1-6546-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-27","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-27","modifiedBy":"ONEDATA","dateModified":"2006-07-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2321361","version":"1","preferredName":"Classification","preferredDefinition":"Classification; the grouping of things into classes or categories.","longName":"C25161","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCF89106-20AF-2D93-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-07-29","modifiedBy":"ONEDATA","dateModified":"2005-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C3ADF7A-C195-2160-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-11","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-11","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".Updated def for CML.  No version needed. AK 12/20/13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2688781","version":"1.1","preferredName":"Chronic Myelogenous Leukemia Type","preferredDefinition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival._Something distinguishable as an identifiable class based on common qualities.","longName":"CML_TP","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Ph unknown / bcr+","valueDescription":"Ph Unknown/BCR+","ValueMeaning":{"publicId":"2688784","version":"1","preferredName":"Ph Unknown/BCR+","longName":"2688784","preferredDefinition":"Philadelphia chromosome abnormality; (9;22)(q34;q11) was not tested; therefore it is not known if it was present or not; bcr/abl gene rearrangement was found. ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ph Unknown/BCR+","conceptCode":"C70623","definition":"Philadelphia chromosome abnormality; (9;22)(q34;q11) was not tested; therefore it is not known if it was present or not; bcr/abl gene rearrangement was found.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C3ACDB1-D5A7-1BF2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-11","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E9689178-AF89-B27C-E040-BB89AD4313AB","beginDate":"2007-10-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"ONEDATA","dateModified":"2013-10-23","deletedIndicator":"No"},{"value":"Ph+ / bcr unknown","valueDescription":"Ph+/BCR Unknown","ValueMeaning":{"publicId":"2688785","version":"1","preferredName":"Ph+/BCR Unknown","longName":"2688785","preferredDefinition":"Philadelphia chromosome abnormality; t(9;22)(q34;q11) was found; bcr/abl gene rearrangement was not tested; therefore it is not known if present or not. ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ph+/BCR Unknown","conceptCode":"C70624","definition":"Philadelphia chromosome abnormality; t(9;22)(q34;q11) was found; bcr/abl gene rearrangement was not tested; therefore it is not known if present or not.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C3ACDB1-D5CE-1BF2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-11","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E9689178-AF9D-B27C-E040-BB89AD4313AB","beginDate":"2007-10-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"ONEDATA","dateModified":"2013-10-23","deletedIndicator":"No"},{"value":"Ph+ / bcr+","valueDescription":"Ph+/BCR+","ValueMeaning":{"publicId":"3326322","version":"1","preferredName":"Ph+/BCR+","longName":"3326322","preferredDefinition":"Philadelphia chromosome abnormality; t(9;22)(q34;q11) was found; bcr/abl gene rearrangement was found.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ph+/BCR+","conceptCode":"C79095","definition":"Philadelphia chromosome abnormality; t(9;22)(q34;q11) was found; bcr/abl gene rearrangement was found.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3862B52-B468-375A-E040-BB89AD436460","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E9689178-AFB1-B27C-E040-BB89AD4313AB","beginDate":"2007-10-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"ONEDATA","dateModified":"2013-10-23","deletedIndicator":"No"},{"value":"Ph+ / bcr-","valueDescription":"Ph+/BCR-","ValueMeaning":{"publicId":"3927358","version":"1","preferredName":"Ph+/BCR-","longName":"3927358","preferredDefinition":"Philadelphia chromosome abnormality; t(9;22)(q34;q11) was found; bcr/abl gene rearrangement was not found.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ph+/BCR-","conceptCode":"C79094","definition":"Philadelphia chromosome abnormality; t(9;22)(q34;q11) was found; bcr/abl gene rearrangement was not found.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9689178-AFBD-B27C-E040-BB89AD4313AB","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E9689178-AFD5-B27C-E040-BB89AD4313AB","beginDate":"2007-10-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"ONEDATA","dateModified":"2013-10-23","deletedIndicator":"No"},{"value":"Ph- / bcr+","valueDescription":"Ph-/BCR+","ValueMeaning":{"publicId":"2688786","version":"1","preferredName":"Ph-/BCR+","longName":"2688786","preferredDefinition":"Philadelphia chromosome abnormality; t(9;22)(q34;q11) was not found; bcr/abl gene rearrangement was found. ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ph-/BCR+","conceptCode":"C70602","definition":"Philadelphia chromosome abnormality; t(9;22)(q34;q11) was not found; bcr/abl gene rearrangement was found.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C3ACDB1-D5F5-1BF2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-11","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E9689178-AFE9-B27C-E040-BB89AD4313AB","beginDate":"2007-10-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"ONEDATA","dateModified":"2013-10-23","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2486811","version":"1","preferredName":"CML Type","preferredDefinition":"The most common chronic myeloproliferative disorder characterized by neutrophilic leukocytosis.  It is associated with the Philadelphia (Ph) chromosome and/or the BCR/ABL fusion gene.  Most patients are middle-aged or elderly.  Common findings at presentation include fatigue, weight loss, anemia, night sweats, and splenomegaly.  The disease is bi- or triphasic: an initial indolent chronic phase is followed by accelerated or blast phase.  Allogeneic bone marrow transplantation is currently the only curative therapy (adapted from WHO 2001).  -- 2003:Type; a subdivision of a particular kind of thing.","longName":"C3174:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3174","definition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"16358911-633C-2575-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-14","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-14","modifiedBy":"ONEDATA","dateModified":"2006-06-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9689178-AEF0-B27C-E040-BB89AD4313AB","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"KUMMEROA","dateModified":"2014-01-08","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"PreTed_prime_dis_hct_cml_class","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedDiagnosis:value","type":"HCT_BRIDG","context":"NHLBI"},{"name":"pre_ted_cml_ph_pos_spec","type":"NMDP_FN","context":"NHLBI"},{"name":"CPRE_ICT_cml_class","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the classification o","type":"Preferred Question Text","description":"What was the classification of the chronic myelogenous leukemia?","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2688790","type":"BRIDG Mapping Path","description":"PerformedDiagnosis.value(ANY=>CD).code","url":null,"context":"NHLBI"},{"name":"Specify CML classification","type":"Alternate Question Text","description":"Specify CML classification","url":null,"context":"NHLBI"},{"name":"Specify CML classification","type":"Application Standard Question Text","description":"Specify CML classification","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9689178-AFF3-B27C-E040-BB89AD4313AB","latestVersionIndicator":"Yes","beginDate":"2007-10-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"ALEYR","dateModified":"2019-04-07","changeDescription":". Added human readable def. System generated def displayed as alt def. No version needed. AK 11/17/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}